If you or your loved one worked with commercial grade RoundUp and have received a diagnosis of non-Hodgkin’s lymphoma, you may have the right to take legal action. Call our product liability attorneys at 800.662.1234 for a free consultation.
Commercial farmers, landscape maintenance workers, orchard workers, nursery workers and groundskeepers are most at risk due to regular exposure by inhaling the herbicide, eye exposure and through skin contact.
Monsanto discovered the potential use of glyphosate as an herbicide in 1970, and today approximately 250 million pounds of the chemical are sprayed worldwide on crops, public parks, commercial nurseries, commercial and residential lawns and golf courses every year. Recent studies found a probable association between repeated exposure to glyphosate and cancers of the lymphatic system and specifically non-Hodgkin lymphoma.
In 2015, the World Health Organization and the International Agency for Research on Cancer classified glyphosate as a probable carcinogen, linking it to many forms of non-Hodgkin’s lymphoma. Glyphosate is currently under review by the United States Environmental Protection Agency to determine if the labels on products such as RoundUp should be changed to include “probable human carcinogen.”
Non-Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. Lymphoma affects the body’s lymphatic system. The lymph system is part of the immune system, which helps fight infections and some other diseases. It also helps fluids move through the body. Lymphomas can start anywhere in the body where lymph tissue is found. Without treatment, it can eventually spread to other parts of the body and result in death.
In 2018, a California jury found in favor of a school groundskeeper and awarded $289 million in damages for failure to warn the plaintiff that Roundup caused cancer. The groundskeeper developed lymphoma after spraying up to 30 times a day over a period of four years. The court later reduced the award to $78 million.
More recently, in March 2019, another California jury awarded $80 million, finding that Roundup was a “substantial factor” in the plaintiff developing non-Hodgkin’s lymphoma. This was the second trial of more than 11,000 cases pending nationwide.